Mercator Medical Q2 2026 EBITDA returns to profit at PLN 46 million; revenue rises 33% year on year to PLN 191 million

• Mercator Medical posted Q2 2026 revenue of PLN 191 million, up 33% year on year.
• EBITDA returned to profit at PLN 46 million, versus a loss a year earlier; net profit swung to PLN 44.4 million.
• Performance improved on higher sales margins, stronger specialist and premium glove sales, and more favorable purchase prices for goods.
• Geopolitical tensions in the Strait of Hormuz lifted prices for diagnostic gloves and non-woven products, supporting market conditions in the quarter.
• End-June net cash and other financial assets totaled about PLN 171.4 million; a PLN 15 million dividend, or PLN 1.64 per share, was paid in August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mercator Medical SA published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.